Deepak Vadehra

The NET-PRO study group led by Michael O’Rorke @uiowa is on a roll this week. Latest in JCTS about how the NET-PRO study used a participation monitoring tool to enhance participation and representation in this rare cancer space. pubmed.ncbi.nlm.nih.gov/41822553/

Something to celebrate- my first lecture as an attending. Had the opportunity to talk with @EmoryMedicine residents about (my favorite thing to talk about)- NETs!! It is my life’s mission to get more people interested in this space— that’s the only way to move the field forward.

RT @Sarbaji85064063: Clinical question: For cT2N0 esophageal cancer, should we proceed with primary surgery or start with neoadjuvant thera…

It’s 2 AM in Atlanta GA and I am live for the mini oral presentation session at #ENETS26 being held in Krakow, Poland 🇵🇱 ready to present our work on early-onset NETs. Sad to miss the meeting in person this year. What a great feast for NEN enthusiasts. @ENETS_ORG @TheGutOncLab @WinshipAtEmory

THAT’S MY BOY

🏆 My first @ENETS_ORG #ENETS26 oral presentation is in the books. So grateful for this opportunity to represent @WinshipAtEmory and present our work on molecular and immune differences in early-onset versus average-onset enteropancreatic neuroendocrine tumors. Couldn’t make it to Krakow 🇵🇱 in person but hope to be there at #ENETS27 Thank you @greeneannac @CureNETs for this picture all the way from Krakow 🇵🇱 I love our NETs community so much 🦓 ❤️

Excited to welcome Kyaw Aung, MBBS, PhD to the GI Medical Oncology team at @BHCancerCare @MiamiCancerInst @BaptistHealthSF Dr. Aung completed his PhD in ctDNA at the University of Manchester, followed by advanced training in Phase I drug development & GI cancers at Princess Margaret Cancer Centre. Most recently he served as a faculty at UT Austin’s Dell Medical School / Livestrong Cancer Institutes. His expertise in pancreatic & hepatobiliary cancers and translational science will be key as we continue to grow our GI research and clinical trials program. Welcome to Miami, Kyaw! #GIOncology #PancreaticCancer #PrecisionOncology #ClinicalTrials

Eagerly looking forward to speaking at the NCAN Patient Conference in Miami ☀️ 🏝️ later this month.

🔥TONIGHT @ASCO #GU26 🔥 Join us for: ❤️Food 🤝Networking 🗣️Live Discussion w/ @OncBrothers @apolo_andrea @UroDocAsh @DrKarineTawagi @AlanBryce9 @montypal @DrChoueiri ✅ Register here: bit.ly/aiogi26 🤩Tag us with event highlights! #OncTwitter #AdvInOnc26 #FOAMed

@SethConcorsMD and I made a field trip to @PoHienEar Lab at @WinshipAtEmory today. So excited about all the great work/projects that we have lined up for our NET team here at Emory. To think about what this means for our patients, makes it even more incredible. 🦓 ❤️ ☕️

The new @ASCO guideline for advanced gastroesophageal cancer is out in @JCO_ASCO Key highlights: • Mandatory upfront biomarker testing (HER2, PD-L1, MSI, CLDN18.2) • IO + chemo for PD-L1 ≥1 (greater benefit ≥10) • Zolbetuximab for CLDN18.2+ • IO + chemo+trastuzumab in HER2+ PD-L1 ≥1 • T-DXd in 2L HER2+ Grateful to @ASCO & @MDmanishshah for the opportunity to contribute. @MiamiCancerInst @BaptistHealthSF @BHCancerCare @OncoAlert @OncUpdates @OncBrothers @oncodaily #GIOncology #ASCOGuidelines ascopubs.org/doi/10.1200/JC…

Gift form a patient, who drove a long distance for a consult with our NET team @WinshipAtEmory “I drove for hope”, they said. So powerful!

Outstanding and highly informative talk by Dr. @Sarbaji85064063 on ADCs in GI cancers, covering target expression patterns, biologic and trial design challenges, and next-generation strategies. A masterclass on where the field is headed. A truly insightful session! @MiamiCancerInst @BrainTumorDoc @oncodaily @OncoAlert #MCIPrecisionOncology

Chief of GI oncology Dr. Sarbajit Mukherjee discusses new implications with ADCs for GI cancers. #MCIPrecisionOncology @Sarbaji85064063

💥#ASCOGI26 #GI26 highlights with @UGrewalMD @TheGutOncLab @WinshipAtEmory and Dr. Laderman @FoxChaseCancer 🤩 ⭐️Hear the 🗣️ on #DYNAMIC III and CIRCULATE trials investigating the role of ctDNA in CRC! How are you using ctDNA in your clinic🤔 #Oncology oncupdates.com/video-podcasts…

🙏🏻 @OncoAlert for reminding me of #WorldCancerDay I am honored everyday to assist in the care of our patients. Pls continue to support #CancerResearch! TY @weoncologists for helping me with the #OncoAlertColloquium today! #UnitedbyUnique

Thank you for the opportunity to share my thoughts on ctDNA in CRC and highlight key areas of unmet need. ctDNA is a powerful tool, but there’s room for assay refinement. We need to rethink endpoint selection and clinical trial design as well- all of which are important steps in the direction of developing a predictive (and not just prognostic) tool for clinical practice. @TheGutOncLab

GI ADC development is becoming more disciplined—and that’s where real differentiation will come from. In my recent discussion with @TargetedOnc, we focused on what matters most for successful ADC programs in GI cancers: •Payload biology drives outcomes more than target

Who really benefits from perioperative immunotherapy in gastric/GEJ cancer? Short answer: biology — and now we have the data. Excited to share our team’s meta-analysis, just published in JNCI Cancer Spectrum (7 RCTs, 2,510 patients). Adding immunotherapy to periop chemotherapy improves outcomes overall: • pCR: 17.6% vs 6.1% • EFS: HR 0.76 • OS: HR 0.82 But the benefit is biologically enriched: • PD-L1+ tumors: ↑ pCR (~19%), ↑ EFS (HR ~0.74), ↑ OS (HR ~0.82) • PD-L1− tumors: no statistically significant pCR, EFS, or OS benefit This aligns closely with the @NCCN guidelines. Huge congratulations to Reo Omori and @waraonc23 for leading and completing this important work 👏 @MiamiCancerInst @BaptistHealthSF @BHCancerCare @RoswellPark @RoswellHemOnc @OUPAcademic @OncBrothers #GastricCancer #GIOncology #Immunotherapy #PrecisionOncology #NCCN #JNCI #CancerResearch #ClinicalTrials #TeamScience academic.oup.com/jncics/article…

🌟 New insights #ASCOGI26/#GI26 #CABINET trial guides cabozantinib use in #NETs post-PRRT, while #STELLAR-303 shows OS 🚀 boost with zanza + IO in MSS #mCRC, +even w/liver mets! #MedTwitter #OncTwitter #GIOnc @ASCO #HemOnc @GIMedOnc @AnwaarSaeed3 🎙️👇 oncupdates.com/video-podcasts…